ITOP4

ITOP4 is a preclinical-stage, off-the-shelf peptide-based cancer vaccine being developed by Infinitopes. It is designed to target a specific, currently undisclosed cancer indication (referred to as "Undisclosed cancer indication #4" in company literature). The vaccine utilizes Infinitopes' proprietary antigen discovery platform to identify and deliver tumor-specific peptides intended to stimulate a robust T-cell mediated immune response against malignant cells. As an "off-the-shelf" product, it is intended for broad use without the need for patient-specific customization, potentially offering a more scalable and cost-effective alternative to personalized neoantigen vaccines.